Erdem Ak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Erdem Ak has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Ali Can Korkmaz
Department of Anatomy, Gulhane Training and Research Hospital, Ankara, Türkiye
1 shared publication - Ali Delibas
MERSİN ÜNİVERSİTESİ, TIP FAKÜLTES
1 shared publication - Ali Duyu
Mersin University Faculty of Medicine, Department of Pediatric Oncology, Mersin, Turkey
1 shared publication - Begül Yağcı-Küpeli
Department of Pediatric Hematology and Oncology, Adana City Training and Research Hospital, University of Health Sciences, Adana, Turkey, akdeniz.edu.tr
1 shared publication - Elvan Caglar Citak
Mersin Univ, Fac Med, Dept Pediat Oncol, Mersin, Turkey
1 shared publication - Gulcin Eskandari
Department of Biochemistry, School of Medicine, Mersin University, Mersin, Turkey
1 shared publication
Latest Publications
- Open Access
- 3 May 2025
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 398 (11) , 15351-15362
Assessment of protective effect of the losartan against cisplatin-induced nephrotoxicity in mice
Cisplatin is widely used in pediatric oncology but is limited by its dose-dependent nephrotoxicity. The renin–angiotensin–aldosterone system (RAAS) has been implicated in cisplatin-induced renal injury. Losartan, an angiotensin II receptor blocker, may offer renal protection; however, its effects on apoptosis and regeneration in this context remain unclear. This study aimed to investigate the potential protective role of losartan against cisplatin-induced nephrotoxicity, specifically by assessing its impact on apoptosis and tubular regeneration. Fifteen female BALB/c mice were randomly assigned to three groups ( n = 5 per group): Control, cisplatin (12.7 mg/kg, i.p., single dose), and cisplatin + losartan (10 mg/kg/day, oral). Losartan was administered for nine consecutive days, starting 4 days before cisplatin exposure. Histopathological examination, active caspase-3 immunostaining (for apoptosis), and 5-bromo-2-deoxyuridine (BrdU) labeling (for cell proliferation) were performed. Glomerular and tubular injury scores, caspase-3 H-scores, and BrdU-positive cell counts were statistically analyzed using the Kruskal–Wallis H and Mann–Whitney U tests. Cisplatin significantly increased glomerular ( p = 0.006, p = 0.005, p = 0.006) and tubular injury scores ( p = 0.008, p = 0.007, p = 0.007, p = 0.007, p = 0.007), elevated active caspase-3 expression ( p = 0.002), and reduced BrdU-positive cell counts ( p = 0.009) compared to control. Losartan co-treatment significantly reduced glomerular ( p = 0.008, p = 0.005, p = 0.008) and tubular injury ( p = 0.008, p = 0.008, p = 0.009, p = 0.008, v) and decreased caspase-3 expression ( p = 0.009). Additionally, BrdU-positive cell counts were significantly higher in the cisplatin + losartan group compared to both control and cisplatin groups ( p = 0.009), indicating enhanced regeneration. Losartan mitigates cisplatin-induced nephrotoxicity by suppressing apoptosis and promoting tubular regeneration. These findings support the potential therapeutic role of RAAS inhibition in preventing cisplatin-associated renal injury.
- 3 May 2025
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 398 (11) , 15351-15362
Open AccessAssessment of protective effect of the losartan against cisplatin-induced nephrotoxicity in mice
Cisplatin is widely used in pediatric oncology but is limited by its dose-dependent nephrotoxicity. The renin–angiotensin–aldosterone system (RAAS) has been implicated in cisplatin-induced renal injury. Losartan, an angiotensin II receptor blocker, may offer renal protection; however, its effects on apoptosis and regeneration in this context remain unclear. This study aimed to investigate the potential protective role of losartan against cisplatin-induced nephrotoxicity, specifically by assessing its impact on apoptosis and tubular regeneration. Fifteen female BALB/c mice were randomly assigned to three groups ( n = 5 per group): Control, cisplatin (12.7 mg/kg, i.p., single dose), and cisplatin + losartan (10 mg/kg/day, oral). Losartan was administered for nine consecutive days, starting 4 days before cisplatin exposure. Histopathological examination, active caspase-3 immunostaining (for apoptosis), and 5-bromo-2-deoxyuridine (BrdU) labeling (for cell proliferation) were performed. Glomerular and tubular injury scores, caspase-3 H-scores, and BrdU-positive cell counts were statistically analyzed using the Kruskal–Wallis H and Mann–Whitney U tests. Cisplatin significantly increased glomerular ( p = 0.006, p = 0.005, p = 0.006) and tubular injury scores ( p = 0.008, p = 0.007, p = 0.007, p = 0.007, p = 0.007), elevated active caspase-3 expression ( p = 0.002), and reduced BrdU-positive cell counts ( p = 0.009) compared to control. Losartan co-treatment significantly reduced glomerular ( p = 0.008, p = 0.005, p = 0.008) and tubular injury ( p = 0.008, p = 0.008, p = 0.009, p = 0.008, v) and decreased caspase-3 expression ( p = 0.009). Additionally, BrdU-positive cell counts were significantly higher in the cisplatin + losartan group compared to both control and cisplatin groups ( p = 0.009), indicating enhanced regeneration. Losartan mitigates cisplatin-induced nephrotoxicity by suppressing apoptosis and promoting tubular regeneration. These findings support the potential therapeutic role of RAAS inhibition in preventing cisplatin-associated renal injury.
- Open Access
- 31 July 2018
- Published by Galenos Yayinevi in Journal of Clinical Research in Pediatric Endocrinology
- Vol. 10 (3) , 198-5
Prevalence and Related Factors of Euthyroid Sick Syndrome in Children with Untreated Cancer According to Two Different Criteria
Objective: In this study, we evaluated the frequency of euthyroid sick syndrome (ESS) among patients with childhood cancer and its association with the stage of disease, nutritional parameters and cytokines levels. Methods: Eighty newly diagnosed children were included in the study. ESS was assessed in two different ways. According to criteria 1 ESS was present if free triiodothyronine (fT3) was below the lower limit and free thyroxine was within the normal or low limits, thyroid-stimulating hormone (TSH) was in the normal range. According to criteria 2, in addition to the above, it was required that reverse triiodothyronine (rT3) be performed and was higher than normal limits. Results: Three of our pediatric patients had subclinical hypothyroidism and two had subclinical hyperthyroidism. Out of 75 patients, ESS was identified in 14 (17.3%) according to criteria 1 and in eight (10.6%) according to criteria 2. Only fT3 levels were significantly different in the ESS (+) and ESS (-) groups (p < 0.05) according to criteria 1. A significantly negative correlation between interleukin (IL)6 and fT3 was found, according to both sets of criteria. tumor necrosis factor alpha was negatively correlated with fT3 levels only in the criteria 1 group. There were no correlations between IL-1 beta and fT3, free thyroxine, rT3 and TSH levels. Conclusion: ESS may occur in childhood cancer and thyroid function testing should be performed routinely when cancer is diagnosed.
- 31 July 2018
- Published by Galenos Yayinevi in Journal of Clinical Research in Pediatric Endocrinology
- Vol. 10 (3) , 198-5
Open AccessPrevalence and Related Factors of Euthyroid Sick Syndrome in Children with Untreated Cancer According to Two Different Criteria
Objective: In this study, we evaluated the frequency of euthyroid sick syndrome (ESS) among patients with childhood cancer and its association with the stage of disease, nutritional parameters and cytokines levels. Methods: Eighty newly diagnosed children were included in the study. ESS was assessed in two different ways. According to criteria 1 ESS was present if free triiodothyronine (fT3) was below the lower limit and free thyroxine was within the normal or low limits, thyroid-stimulating hormone (TSH) was in the normal range. According to criteria 2, in addition to the above, it was required that reverse triiodothyronine (rT3) be performed and was higher than normal limits. Results: Three of our pediatric patients had subclinical hypothyroidism and two had subclinical hyperthyroidism. Out of 75 patients, ESS was identified in 14 (17.3%) according to criteria 1 and in eight (10.6%) according to criteria 2. Only fT3 levels were significantly different in the ESS (+) and ESS (-) groups (p < 0.05) according to criteria 1. A significantly negative correlation between interleukin (IL)6 and fT3 was found, according to both sets of criteria. tumor necrosis factor alpha was negatively correlated with fT3 levels only in the criteria 1 group. There were no correlations between IL-1 beta and fT3, free thyroxine, rT3 and TSH levels. Conclusion: ESS may occur in childhood cancer and thyroid function testing should be performed routinely when cancer is diagnosed.